Page last updated: 2024-12-07
ritalinic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 86863 |
CHEBI ID | 83481 |
SCHEMBL ID | 1462581 |
MeSH ID | M0053672 |
Synonyms (44)
Synonym |
---|
ritalinic acid , |
ritalinic acid, 99% (cp) |
19395-41-6 |
FT-0653505 |
phenyl(piperidin-2-yl)acetic acid |
2-phenyl-2-piperidin-2-ylacetic acid |
phenyl(2-piperidinyl)acetic acid;2-phenyl-2-piperidineacetic acid |
A19443 |
2-piperidineacetic acid, alpha-phenyl- |
einecs 243-020-7 |
alpha-phenylpiperidine-2-acetic acid |
alpha-phenyl-2-piperidineacetic acid |
SCHEMBL1462581 |
2-phenyl-2-piperidineacetic acid |
2-phenyl-2-(piperidin-2-yl)acetic acid |
phenyl(2-piperidinyl)acetic acid |
FS-3198 |
AKOS015892837 |
S5251 |
CHEBI:83481 |
mfcd06200695 |
SY030346 |
2-phenyl-2-(2-piperidyl)acetic acid |
2-phenyl-2-(2-piperidyl) acetic acid |
phenyl(2-piperidinyl)acetic acid # |
R0111 |
2-phenyl-2-piperidineacetic acid, 98% |
ritalinic acid, analytical standard |
AC-8122 |
ritalinic acid; methylphenidate related compound a |
CS-W022954 |
FT-0674441 |
FT-0674440 |
FT-0674442 |
FT-0674439 |
FT-0674435 |
BCP07811 |
DTXSID20864888 |
FT-0674443 |
Q17052328 |
l-threo-ritalinic acid;(2s)-2-phenyl-2-[(s)-2-piperidinyl]acetic acid |
BCP26035 |
FT-0674438 |
EN300-7375458 |
Research Excerpts
Effects
Excerpt | Reference | Relevance |
---|---|---|
"Ritalinic acid has further been detected in German rivers at concentrations of 4-23 ngL(-1) and in bank filtrate samples in 100-850 m distance from the river up to 5 ngL(-1) demonstrating the widespread occurrence of this stable metabolite in the aquatic environment." | ( Occurrence and fate of the human pharmaceutical metabolite ritalinic acid in the aquatic system. Letzel, M; Schüssler, W; Sengl, M; Weiss, K, 2010) | 1.33 |
Pharmacokinetics
Methylphenidate concentrations were not markedly affected by ethanol, but ritalinic acid concentrations were lower. For the first time a physiologically based pharmacokinetic (PBPK) model has been developed.
Excerpt | Reference | Relevance |
---|---|---|
" MPH and RA were both detected in oral fluid with a pharmacokinetic profile similar to that in plasma." | ( Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. Farrè, M; García-Algar, O; Marchei, E; Pacifici, R; Pellegrini, M; Pichini, S; Vall, O, 2010) | 0.36 |
" The pharmacokinetic evaluation showed that methylphenidate concentrations were not markedly affected by ethanol, but ritalinic acid concentrations were lower, especially if ethanol was ingested first." | ( Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate. Kauert, GF; Koehm, M; Toennes, SW, 2010) | 0.8 |
" For the first time a physiologically based pharmacokinetic (PBPK) model has been developed in juvenile and adult humans and nonhuman primates to quantitatively evaluate species- and age-dependent enantiomer specific pharmacokinetics of MPH and its primary metabolite ritalinic acid." | ( Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. Doerge, DR; Fisher, JW; Gearhart, JM; Mattison, DR; Morris, SM; Paule, MG; Ruark, CD; Slikker, W; Twaddle, NC; Vitiello, B; Yang, X; Young, JF, 2014) | 0.58 |
" The objectives of the current study were to describe drug concentrations, develop an analytical method that could be used to regulate its use, and describe the pharmacodynamic effects of ethylphenidate in horses." | ( L- and D-threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses. Benson, D; Hartmann, P; Hovda, L; Knych, HK; McKemie, DS; Seminoff, K, 2018) | 0.48 |
Bioavailability
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" An essential component of such studies is the determination of MP plasma levels under chronic and acute dosing conditions." | ( Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. Bajic, S; Doerge, DR; Fogle, CM; McCullagh, M; Paule, MG, 2000) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
Role | Description |
---|---|
marine xenobiotic metabolite | Any metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms. |
drug metabolite | null |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
---|---|
monocarboxylic acid | An oxoacid containing a single carboxy group. |
piperidines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (54)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 11 (20.37) | 18.7374 |
1990's | 5 (9.26) | 18.2507 |
2000's | 8 (14.81) | 29.6817 |
2010's | 25 (46.30) | 24.3611 |
2020's | 5 (9.26) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 46.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.80) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 5 (8.62%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (3.45%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 51 (87.93%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |